COVID-19 Vaccination Timing After Monoclonal Antibody or Convalescent Plasma Treatment
Patients who received SARS-CoV-2 monoclonal antibodies or convalescent plasma as treatment for COVID-19 should defer vaccination for at least 90 days following receipt of antibody therapy. 1, 2, 1
Rationale for the 90-Day Deferral
The 90-day waiting period is based on CDC guidance and has been consistently incorporated into multiple professional society guidelines. This recommendation stems from theoretical concerns about:
- Interference with vaccine-induced immunity: Passively administered antibodies may interfere with the body's ability to mount an active immune response to vaccination
- Antibody competition: Exogenous antibodies could potentially neutralize vaccine antigens before the immune system can respond appropriately
- Duration of passive immunity: The therapeutic antibodies typically persist for approximately 90 days, after which endogenous immune responses become more important
Key Clinical Considerations
After Recovery from Acute Illness
Once patients have recovered from their acute COVID-19 illness (if symptomatic) and discontinued isolation, they should wait until the 90-day period has elapsed before receiving vaccination 1, 2, 1. The vaccine should then be administered without further delay after this waiting period.
For Two-Dose Vaccine Series
If a patient develops SARS-CoV-2 infection and receives monoclonal antibodies or convalescent plasma between the first and second dose of a two-dose vaccine series:
- Delay the second dose until recovery from acute illness
- Wait the full 90 days from antibody therapy
- Then complete the vaccine series without additional delay 1, 2
Important Caveats
Recent Evidence on Vaccine Response
Emerging data suggests that prior monoclonal antibody treatment may limit endogenous receptor-binding domain (RBD)-focused B-cell responses to subsequent mRNA vaccination, though T-cell immunity appears unaffected 3. This finding supports the importance of appropriate timing between antibody therapy and vaccination.
Immunocompromised Populations
While the 90-day deferral applies broadly, immunocompromised patients face unique considerations:
- These patients may have suboptimal responses to both passive antibody therapy and vaccination
- The guidelines from rheumatology 1 and hematology/oncology 4 emphasize that vaccination should still occur after the 90-day period
- Some immunocompromised patients may benefit from additional vaccine doses or antibody testing after vaccination, though routine testing is not recommended for most patients
Current Plasma Antibody Levels
Recent data shows that conventional plasma units now contain SARS-CoV-2 neutralizing antibodies at levels comparable to COVID-19 convalescent plasma 5, which may influence future guidance as population immunity evolves.
Practical Implementation
Do not vaccinate patients currently receiving or who have recently received (within 90 days):
- Bamlanivimab
- Casirivimab/imdevimab
- Tixagevimab/cilgavimab
- Amubarvimab/romlusevimab
- COVID-19 convalescent plasma
Proceed with vaccination after:
- 90 days have elapsed from antibody therapy
- Patient has recovered from acute illness (if applicable)
- Isolation period has been completed (if applicable)
This recommendation represents strong consensus across multiple guideline bodies including the American College of Rheumatology 1, 2, 1 and the European Conference on Infections in Leukaemia 4, all citing alignment with CDC guidance.